News : Phase II study

Diamyd Medical announced today that the company’s 4-year follow-up of type 1 diabetes patients included in the company’s Phase II study shows a clear positive trend.
Diamyd Medical received approval from the Swedish Medical Products Agency in February to follow up the children and adolescents with type 1 diabetes that were included in the company’s previously reported Phase II study with the diabetes vaccine...

Diamyd Medical has received approval from the Swedish Medical Products Agency to continue to follow the children who participated in the company’s Phase II study of the Diamyd® diabetes vaccine, which started four years ago. The aim of the follow-up study is to confirm the vaccine’s long-term effect.
“Clinical studies with Diamyd® have demonstrated significant efficacy in preserving the body’s own ability to...